Heart Diseases | miR-221/222 | CAD | Promote the progression of CAD | [103] |
miR-208a | CAD | Promote the progression of CAD | [104] |
miR-126 | CAD | Inhibit the progression of CAD | [105] |
miR-17-92 | CAD | Inhibit the progression of CAD | [106] |
miR-22 | AMI | Protect against CMCs apoptosis | [108] |
miR-133 | AMI | Promote the progression of AMI | [109] |
miR-21 | AMI, HF | Promote CMCs loss | [110, 113] |
miR-24 | HF | Promote the progression of HF | [114] |
miR-214 | HF | Promote the progression of HF | [115] |
Hypertension | miR-211 | EH | Activate the axis of RAAS | [119] |
miR-615 | EH | Activate the axis of RAAS | [119] |
miR-155 | EH | Regulate the progression of VC | [99] |
Cerebrovascular Diseases | miR-126 | AIS | Inhibit microglial activation and inflammatory response | [122] |
miR-30d-5p | AIS | Inhibit autophagy-mediated microglial polarization to M1 | [123] |
miR-181b-5p | AIS | promoted BMEC angiogenesis | [37] |
miR-146a | VCID | Inhibit inflammatory effects on damaged astrocytes | [124] |
Kidney Diseases | miR-200b | CKD | Regulate the progression of renal fibrosis | [126] |
miR-16 | CKD | Regulate the progression of CKD | [127] |
PAD | miR-92a | Hind Limb Ischemia | Inhibit functional recovery | [129] |